Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: methotrexate

RA Drug Tested & FDA Orders Drug-Interaction Studies for Kayexalate

Michele B. Kaufman, PharmD, BCGP  |  November 11, 2015

In multiple trials, baricitinib has proved promising for treating RA. Also, the FDA is requiring drug-interaction studies for sodium polystyrene sulfonate…

Filed under:Biologics/DMARDsDrug Updates Tagged with:baricitinibdrug interactionFDAFood and Drug Administrationsodium polystyrene sulfonate

German Registry Evaluates Systemic Psoriasis Treatments

Michele B. Kaufman, PharmD, BCGP  |  November 4, 2015

The German Psoriasis Registry, PsoBest, found conventional systemic and biologic drugs for psoriasis demonstrated relative safety from serious adverse events in patients between January 2008–December 2012…

Filed under:Biologics/DMARDsDrug Updates Tagged with:BiologicsGermanyMethotrexatePsoriasis

J&J’s Stelara Succeeds in Phase 3 Crohn’s Disease Trial

Bill Berkrot  |  October 22, 2015

(Reuters)—Johnson & Johnson’s Stelara (ustekinumab) was significantly better than placebo at inducing clinical response and remissions in patients with moderate to severe Crohn’s disease, according to data from a late stage trial, providing ammunition for a potential expanded approval of the medicine. Stelara, a biotech medicine that blocks inflammation, is approved to treat plaque psoriasis…

Filed under:Biologics/DMARDsDrug Updates Tagged with:Crohn's diseaseustekinumab

Rituximab May Benefit Patients with Refractory JIA-Associated Uveitis

Lorraine L. Janeczko  |  October 21, 2015

NEW YORK (Reuters Health)—Rituximab may calm juvenile idiopathic arthritis (JIA)-associated uveitis and especially benefit patients who haven’t responded to other biologic treatments, a study from Italy suggests. With its convenient dosing schedule, rituximab may be a new treatment option for patients with autoimmune diseases, especially for those who have not responded to tumor necrosis factor…

Filed under:Biologics/DMARDsDrug Updates Tagged with:Anti-TNFJuvenile Arthritis (JIA)rituximabTNFUveitis

FDA Warns ‘Don’t Use Tramadol in Children’ & More

Michele B. Kaufman, PharmD, BCGP  |  October 21, 2015

New studies show ABT-494 is an effective alternative to anti-TNF alpha agents, as well as methotrexate, for RA. Also, the FDA issued a warning against using tramadol for young patients due to their increased risk of respiratory side effects…

Filed under:Drug Updates

Musculoskeletal Ultrasound: A Valuable Tool for Diagnosing Rheumatic Illnesses

Musculoskeletal Ultrasound: A Valuable Tool for Diagnosing Rheumatic Illnesses

Khushboo Sheth, MBBS, & Christopher Scola, MD  |  October 15, 2015

Musculoskeletal (MSK) ultrasound is a valuable imaging modality for the practicing rheumatologist and provides an efficient tool with high diagnostic value in the evaluation of patients with musculoskeletal complaints. The use of MSK ultrasound has evolved in the U.S. due to the emergence of less-expensive, portable ultrasound units, which provide high-quality gray-scale and power Doppler…

Filed under:ConditionsRheumatoid Arthritis Tagged with:ClinicalDiagnosisMSKMusculoskeletal Ultrasoundpatient careRARheumatoid arthritisrheumatologistsrheumatologyTrainingUltrasound

FDA Issues Stronger Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Warning

Michele B. Kaufman, PharmD, CGP, RPh  |  October 14, 2015

The U.S. Food and Drug Administration (FDA) has toughened the existing warnings for nonsteroidal anti-inflammatory drugs (NSAIDs) due to their stroke and myocardial infarction (MI) risk increase.1 Due to a continual review of these products, FDA is requiring label updates for all prescription NSAIDs. Over-the-counter (OTC) NSAIDs already list the increased risk of MI and…

Filed under:ConditionsDrug UpdatesOther Rheumatic ConditionsResearch Rheum Tagged with:abaloparatideadverse eventsanti-inflammatoryclinical trialsdrugFDAMIMyocardial infarctionnonsteroidal anti-inflammatory drugsNSAIDsoutcomeResearchrheumatologyriskSafetystroketofacitinib citrate

Heart Disease: Major Risk Factor for Many Rheumatology Patients

Vanessa Caceres  |  October 14, 2015

Rheumatic diseases, such as rheuma­toid arthritis (RA), systemic lupus erythematosus (SLE) and vasculitis, can affect the body in many ways, but perhaps the most serious is the increased risk of heart disease for many patients. As the risk of atherosclerosis in autoimmune disease patients gains increased attention, rheumatologists and cardiologists are collaborating more often to…

Filed under:ConditionsRheumatoid Arthritis Tagged with:cardiologistsClinicalHeart Diseasepatient careRARheumatoid arthritisrheumatologistrisk

Rituximab for RA Is Safe Long Term, Plus Oxycodone Update

Michele B. Kaufman, PharmD, BCGP  |  September 30, 2015

Rituximab was evaluated and found safe as a long-term RA therapy. Also, FDA Advisory Committees voted on oxycodone therapies at a joint meeting.

Filed under:AnalgesicsBiologics/DMARDsDrug Updates Tagged with:analgesicFDAFood and Drug AdministrationOxycodoneRheumatoid Arthritis (RA)rituximab

New Labeling for Infused Golimumab; Phase 3 Trial for Romosozumab Promising

Michele B. Kaufman, PharmD, BCGP  |  September 16, 2015

The FDA has approved new labeling for infused golimumab to include measures of mental and physical health. Plus romosozumab meets primary endpoints in postmenopausal women with osteoporosis during a Phase 3 trial…

Filed under:Biologics/DMARDsConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:combination therapyFDAFood and Drug AdministrationGolimumabInjectionMental HealthMethotrexateOsteoporosispostmenopauseromosozumab

  • « Previous Page
  • 1
  • …
  • 72
  • 73
  • 74
  • 75
  • 76
  • …
  • 106
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences